Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.

Lancet 2009 May;373(9676):1681-92

Guy's and St Thomas' NHS Trust, London, UK.

Background: Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.

Methods: In this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated permuted block randomisation to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m(2) at 3-weekly intervals) for four cycles (n=2073) or control (n=2089). For the control regimen, centres chose either FEC for eight cycles (n=1265) or epirubicin (100 mg/m(2) at 3-weekly intervals) for four cycles followed by CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) at 4-weekly intervals) for four cycles (n=824). The primary endpoint was disease-free survival. Analysis was by intention to treat (ITT). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN79718493.

Findings: All randomised patients were included in the ITT population. With a median follow-up of 62 months, disease-free survival events were seen in 517 of 2073 patients in the experimental group compared with 539 of 2089 controls (hazard ratio [HR] 0.95, 95% CI 0.85-1.08; p=0.44). 75.6% (95% CI 73.7-77.5) of patients in the experimental group and 74.3% (72.3-76.2) of controls were alive and disease-free at 5 years. The proportion of patients who reported any acute grade 3 or 4 adverse event was significantly greater in the experimental group than in the control group (p<0.0001); the most frequent events were neutropenia (937 events vs 797 events), leucopenia (507 vs 362), and lethargy (456 vs 272).

Interpretation: This study did not show any overall gain from the addition of docetaxel to standard anthracycline chemotherapy. Exploration of predictive biomarker-defined subgroups might have the potential to better target the use of taxane-based therapy.

Funding: Cancer Research UK (CRUK 01/001), Sanofi-Aventis, Pfizer, and Roche.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(09)60740-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939PMC
May 2009
64 Reads

Publication Analysis

Top Keywords

600 mg/m2
16
intervals cycles
16
experimental group
12
early breast
12
3-weekly intervals
12
breast cancer
12
mg/m2 3-weekly
12
controlled trial
12
randomised controlled
12
open-label phase
8
iii randomised
8
disease-free survival
8
100 mg/m2
8
phase iii
8
patients experimental
8
mg/m2
8
fluorouracil 600
8
cyclophosphamide 600
8
sequential docetaxel
8
cycles
5

Altmetric Statistics

Similar Publications